As of 18 Sept 2026, Jagsonpal Pharmaceuticals Ltd share price is ₹227.75. The stock opened at ₹227.75 and had closed at ₹228.10 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹154.90 and a high of ₹264.65. In terms of performance, Jagsonpal Pharmaceuticals Ltd share price has increased by 25.48% over the past six months and has decreased by 6.18% over the last year.
JAGSNPHARM Stock Price Chart
Jagsonpal Pharmaceuticals Ltd Overview
About JAGSNPHARM
Jagsonpal Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients.
Jagsonpal Pharmaceuticals Ltd Historical Performance
Jagsonpal Pharmaceuticals Ltd Fundamentals
Jagsonpal Pharmaceuticals Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 299.23 | 276.91 | 217.98 | 242.44 | 221.01 |
| EBITDA | 67.99 | 78.95 | 32.34 | 36.43 | 28.46 |
| Net Profit | 43.08 | 55.36 | 22.46 | 26.72 | 18.86 |
| EPS | 6.40 | 8.26 | 8.49 | 10.20 | 7.20 |
Jagsonpal Pharmaceuticals Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 220.48 |
| Resistance 1 (R1) | 233.48 |
| Pivot Point | 225.87 |
Jagsonpal Pharmaceuticals Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 04-Sep-2026 | 27-Apr-2026 | 04-Sep-2026 | Final | ₹4.00 |
| 12-Sep-2025 | 06-May-2025 | 12-Sep-2025 | Final | ₹2.50 |
| 06-Sep-2024 | 20-May-2024 | 06-Sep-2024 | Final | ₹5.00 |
| 21-Aug-2023 | 23-May-2023 | 21-Aug-2023 | Final | ₹5.00 |
| 29-Oct-2021 | 19-Oct-2021 | 01-Nov-2021 | Interim | ₹4.00 |
JAGSNPHARM Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| Manish Gupta | Managing Director |
| Harsha Raghavan | Chairperson |
| Pallavi Dinodia | Non Executive Independent Director |
Jagsonpal Pharmaceuticals Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Sun Pharmaceutical Industries LtdSUNPHARMA | ₹1,867.30+0.74% | ₹4,19,727.66 | 38.32 | 13.74% |
| Divis Laboratories LtdDIVISLAB | ₹9,323.00+1.80% | ₹1,67,235.91 | 67.46 | 15.32% |
| Torrent Pharmaceuticals LtdTORNTPHARM | ₹4,875.00+1.30% | ₹1,46,951.32 | 64.68 | 25.49% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of Jagsonpal Pharmaceuticals Ltd today is ₹227.75 on NSE and ₹227.75 on BSE.
- The 52-week high of Jagsonpal Pharmaceuticals Ltd is ₹264.65, while the 52-week low is ₹154.90.
- The current market capitalisation of Jagsonpal Pharmaceuticals Ltd is approximately ₹1,502 crore.
- The P/E (Price-to-Earnings) ratio of Jagsonpal Pharmaceuticals Ltd is 33.06. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of Jagsonpal Pharmaceuticals Ltd is 5.47. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy Jagsonpal Pharmaceuticals Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for JAGSNPHARM on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, Jagsonpal Pharmaceuticals Ltd has delivered a return of approximately 31.74%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of Jagsonpal Pharmaceuticals Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 69.05% promoters, 2.30% FIIs, 0.62% DIIs, and 19.33% public shareholders.

